G. Penco

发表

Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.

W. G. Nichols, J. Molina, G. Pialoux, 2009, The Journal of antimicrobial chemotherapy.

Tenofovir renal safety in HIV-infected patients: results from the SCOLTA Project.

E. Ricci, P. Bonfanti, T. Quirino, 2008, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Low frequency of skin reactions in a cohort of patients on raltegravir.

A. Antinori, E. Ricci, P. Bonfanti, 2012, The Journal of antimicrobial chemotherapy.

Weight Gain: A Possible Side Effect of All Antiretrovirals

L. Calza, A. Antinori, E. Ricci, 2017, Open forum infectious diseases.

Impact of transmitted HIV-1 drug resistance on the efficacy of first-line antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor

M. Zazzi, M. Colafigli, A. De Luca, 2018, The Journal of antimicrobial chemotherapy.

Vitamin D deficiency in HIV-infected patients: a systematic review

A. Giusti, G. Pioli, G. Penco, 2011 .

Efficacy and safety of boosted and unboosted atazanavir‐containing antiretroviral regimens in real life: results from a multicentre cohort study

E. Gianelli, E. Ricci, P. Bonfanti, 2010, HIV medicine.

Prevalence and determinants of resistance mutations in HIV‐1‐infected patients exposed to integrase inhibitors in a large Italian cohort

M. Zazzi, A. De Luca, D. Francisci, 2018, HIV medicine.

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

R. Haubrich, M. Kozal, K. Tashima, 2014, The Journal of infectious diseases.

Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: Results from the SCOLTA project long-term surveillance.

E. Ricci, P. Bonfanti, A. di Biagio, 2015, International journal of antimicrobial agents.

Low incidence of hepatotoxicity in a cohort of HIV patients treated with lopinavir/ritonavir

E. Ricci, P. Bonfanti, T. Bini, 2005, AIDS.

Class 1 integron-associated spread of resistance regions in Pseudomonas aeruginosa : plasmid or chromosomal platforms ?

A. Antinori, T. Quirino, L. Cordier, 2012 .

Symmetric ambulatory arterial stiffness index and 24-h pulse pressure in HIV infection: results of a nationwide cross-sectional study

G. Pucci, G. Schillaci, P. Bonfanti, 2013, Journal of hypertension.

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

B. Gazzard, K. Tashima, M. Shields, 2019, The Lancet.

Identifying HIV patients with an unfavorable cardiovascular risk profile in the clinical practice: results from the SIMONE study.

G. Schillaci, E. Ricci, P. Bonfanti, 2008, The Journal of infection.

Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA Project

L. Calza, E. Ricci, K. Falasca, 2018, Infection and drug resistance.

Gender differences in HIV infection: is there a problem? Analysis from the SCOLTA cohorts.

E. Ricci, P. Bonfanti, A. di Biagio, 2014, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort.

D. Francisci, D. Giannarelli, P. Cicconi, 2013, The Journal of antimicrobial chemotherapy.

Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010.

M. Colafigli, S. Di Giambenedetto, C. Torti, 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

The role of baseline HIV‐1 RNA, drug resistance, and regimen type as determinants of response to first‐line antiretroviral therapy

M. Zazzi, A. De Luca, I. Schiavetti, 2014, Journal of medical virology.

Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy: evolution over 12 years and predictors.

R. Maserati, M. Zazzi, M. Colafigli, 2009, The Journal of antimicrobial chemotherapy.

Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus

A. Lazzarin, L. Calza, V. Vullo, 2018, The Journal of antimicrobial chemotherapy.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

A Prognostic Model for Estimating the Time to Virologic Failure in HIV-1 Infected Patients Undergoing a New Combination Antiretroviral Therapy Regimen

et al., Andrea De Luca, Mattia C. F. Prosperi, 2011, BMC Medical Informatics Decis. Mak..

Safety and durability in a cohort of HIV-1 positive patients treated with once and twice daily darunavir-based therapy (SCOLTA Project).

E. Ricci, P. Bonfanti, A. di Biagio, 2013, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

[Renal toxicity in HIV-infected patients receiving HAART including tenofovir].

E. Ricci, P. Bonfanti, T. Quirino, 2006, Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive.

Tossicità renale in pazienti con infezione da HIV in trattamento con HAART contenente tenofovir Renal toxicity in HIV-infected patients receiving HAART includine tenofovir

E. Ricci, P. Bonfanti, T. Quirino, 2006 .

Impact of circulating resistance-associated mutations on HIV pre-exposure prophylaxis (PrEP) efficacy: Modeling from antiretroviral resistance cohort analysis (ARCA) national database.

M. Gismondo, M. Zazzi, V. Borghi, 2016, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Raltegravir-based therapy in a cohort of HIV/HCV co-infected individuals.

E. Ricci, P. Bonfanti, L. Taramasso, 2015, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Decreasing cardiovascular risk in HIV infection between 2005 and 2011

G. Pucci, G. Schillaci, E. Ricci, 2014, AIDS.

Study of beta-2 microglobulin and neopterin in serum and cerebrospinal fluid of HIV-infected patients.

M. Farinelli, F. Emanuelli, L. Arata, 1990, Acta neurologica.

Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting.

A. Calcagno, A. D’Avolio, M. Lanzafame, 2009, Journal of acquired immune deficiency syndromes.

No pol mutation is associated independently with the lack of immune recovery in patients infected with HIV and failing antiretroviral therapy

G. Filice, M. Zazzi, A. De Luca, 2011, Journal of medical virology.

Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database.

R. Maserati, M. Zazzi, A. De Luca, 2013, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

The feature of Metabolic Syndrome in HIV naive patients is not the same of those treated: results from a prospective study.

A. Antinori, E. Ricci, P. Bonfanti, 2012, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Is metabolic syndrome associated to HIV infection per se? Results from the HERMES study.

P. Vitiello, E. Ricci, P. Bonfanti, 2010, Current HIV research.

Metabolic Syndrome: A Real Threat for HIV-Positive Patients?: Results from the SIMONE Study

E. Ricci, P. Bonfanti, G. Parruti, 2006, Journal of acquired immune deficiency syndromes.

Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: results from a multicenter study

E. Ricci, P. Bonfanti, G. Parruti, 2010, Journal of the International AIDS Society.

Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients.

M. Gismondo, G. Filice, M. Zazzi, 2012, Clinical Microbiology and Infection.

Vinca alkaloids and macrolides in human immunodeficiency virus-related malignancies: a safe association

A. Torresin, G. Cassola, G. Penco, 1996, Cancer Chemotherapy and Pharmacology.

Statins and Aspirin use in HIV-infected people: gap between European AIDS Clinical Society guidelines and clinical practice: the results from HIV-HY study

L. Calza, E. Ricci, P. Bonfanti, 2016, Infection.

Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database.

R. Maserati, M. Zazzi, P. Vitiello, 2013, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007-2009.

M. Prosperi, M. Zazzi, S. Paolucci, 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Vitamin D deficiency in HIV-infected patients: a systematic review

A. Giusti, G. Pioli, G. Penco, 2011 .

Darunavir-based dual therapy of treatment-experienced HIV-infected patients: analysis from a national multicenter database

A. Antinori, G. Sterrantino, M. Biondi, 2015, Infection.

Evolution of transmitted HIV‐1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016

M. Gismondo, O. Turriziani, M. Zazzi, 2018, HIV medicine.

Cholesterol levels in HIV-HCV infected patients treated with lopinavir/r: results from the SCOLTA project.

E. Gianelli, E. Ricci, P. Bonfanti, 2008, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.